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1) (a) Epzirtzest; ef Chernisrry, (5) Eepartrnent of Surgery 
The diazonium salt of 1 -(4 -aminophenyl) -lf2-dicarba-closo- 
dodecaborane(l2) has been incorporated into anti-bovine serum albumin 
and antibody proteins specific to human and mouse histocompatibility 
antigens. The incorporation of the boron -label (natural isotopic abun - 
dance) into the antibody is accomplished under sufficiently mild condi - 
tions so as to have minimal effect on the activity and specificity of the 
resulting boron -labeled antibody. The amount of boron incorporated 
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into the antibody is sufficient to cause specific cellular destruction 
when subjected to neutron radiation in vitro. It has also been demon- -- 
strated that particulate boron (natural isotopic abundance) is incorpo - 
rated into Walker 256 cells which can be specifically destroyed with 
neutron radiation. 
The significance of these results using boron-labeled antibodies 
and elemental boron strongly suggests that the concept of incorporating 
boron into proteins which exhibit marked tumor -specificity is of great 
potential for use  in neutron-capture therapy. 
The potential use of boron -containing compounds in cancer therapy 
is based on the unique nuclear property of the boron-10 nucleus to 
absorb thermal neutrons. This approach to cancer therapy is based 
oncthe liberation of high-energy fission fragments following neutron 
capture. The incident thermal neutrons have a relatively low energy 
(0.025 ev) which gives rise to a very high energy a-particle (2.4 MeV) 
following capture by 'OB and fission. 
The essential factors for the selective destruction of tumors have 
The major requirements for the successful appli - 7 3  been reviewed. --' 
(2) A .  H. Soloway, in "Progress in Boron Chemistry, " A .  L. 
McCloskey and H. Steinberg, Ed. , Pergamon Press, Inc., New York, 
N.Y.  , 1964, pp. 203-234. 
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(3) G. L. Brownell, A .  H. Soloway, and W. H. Sweet, "Boron 
Capture Therapy, in "Modern Trends in Radiotherapy, T. J. Deeley 
and C. A.  P. Wood, Ed., Butterworths, Inc., London, 1967, pp. 132-145. 
cation neutron capture therapy are: first ,  there musx be a large con- 
centration of 'OB in all a reas  of the neoplasm (15 mg "B/kg of tumor ). 3 
This requires that the boron compound be injected intravenously and 
not directly into the suspected tumor area since the precise dimensions 
and configuration of the invasive neoplastic process i s  not clearly de- 
lineated. Second, a source must be available to irradiate the neoplastic 
area with a sufficient number of thermal neutrons to cause cellular 
destruction (10 neutrons/cm ). Third, a sufficiently large concen- 12 2 4  
(4) L. E. F a r r  and T. Konikowslti, Inter. Jour.  of App. Rad. and 
Isotopes, 19, 459 (1968). 
tration differential of 'OB between the neoplasm and adjacent normal 
:I 
tissue must exist to permit the complete eradication of the tumor without 
adversely affecting tissue surrounding the neoplasm. 
The primary emphasis for all of the previous studies of neutron- 
capture therapy is the syntheses of boron compounds which exhibit su i t -  
able structure-activity relationships for specific binding to neoplasms. This 
approach has met with only minimal success in fulfilling the requirement 
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5 10 for neoplasm destruction. The possibility of using B -containing 
(5) A. H. Soloway, H. Hatanaka, and M. A .  Davis, J. Med. Chem., 
10, 714 (1967). 
Hy 
antibodies for use in neutron-capture therapy has been suggested. 
basis for this approach is that antibodies a r e  formed in response to the 
The 
administration of an antigen and react specifically with that antigen. 
Consequently, if 'OB could be incorporated into a tumor specific antibody 
protein, the antibody would subsequently concentrate the boron in the 
region of the tumor cell antigen and the cell might then be destroyed by 
subsequent thermal neutron radiation. This paper describes our initial 
exploratory research based upon this concept and provides encouragement 
forfuture work. 
-Results and Discuss ion 
BSA -anti-BSA. The chemical modifications required for B incorpora - 10 
tion a r e  based on the extensive research which has been performed in 
Proteins, including serum the area of fluorescent protein tracing. 6 7  7 
(6) "Fluorescent Antibody Techniques and their Applications, " 
Akiyoshi Kawamura, Jr., Ed., University of Tokyo Press, 1969. 
(7) R. L. Nairn, "Fluorescent Protein Tracing, " 3rd Edition, The 
Williams and Wilkins Company, 1969. 
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antibodies, can be labeled with fluorescent dyes without material effect 
on their biological properties. The fluorescent proteins are then de- 
tectable in tracing experiments by fluorescence microscopy. Tracing 
may be carried out directly by injection of labeled proteins and subse- 
quent histological exam ination, or by the application of immunological 
principles in which labeled antibody is used as a specific histochemical 
stain for antigenic materials in tissues. 
Our first investigation of the applicability of this method used .the 
The purpose of this experiment was to 
8 
standard precipirin reaction. 
(8) D. H. Campbell, J. S. McGarvey, N. E. Cremer, and D. H. 
Sussdorf, "Methods in Immunology, " W. A .  Benjamin, Inc., New York, 
'1964. 
determine if a boron-containing compound could be attached to an anti- 
body protein under sufficiently mild conditions so as to have minimal 
effect on the resulting labeled antibody specificity. The modification 
9 of the antibody was based on results of anti-hapten antibody labeling. 
~~~ 
(9) D. Pressman and A .  L. Grossberg, "The Structural Basis of 
Antibody Specificity, " W. A .  Benjamin, Inc., New York, 1968. 
The boron compound which served a s  the precursor in subsequent diazo 
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coupling reactions was 1 -(4 -aminophenyl) - 1 , 2  -dicarba -closo-dode - 
caborane(l2) which contained a natural abundance of boron isotopes 
(2vo B) and was converted to the corresponding diazonium ion for 
u s e  as a labeling reagent containing a high total boron content. The 
preparation of this compound has previously been reported, and the 
10 
10 
(lo) M. F. Hawthorne, T. E. Berry, andP. A .  Wegner, J. Amer. 
Chem. SOC., 87, 4746 (1965). 
CCN 
synthesis is outlined in Figure 1. The diazonium salt of this compound 
Fig. 1 
could couple to antibody proteins through tyrosine, his tidine and lysine 
groups. 9 
The 7s fraction of rabbit anti-bovine serum albumin (anti-BSA) was 
coupled with the diazonium salt in a phosphate buffered (pH = 8.0) aque- 
0 ous solution at  4 . me resulting yellow (&,ax = 350 nm) boron-labeled 
antibody solution was purified and the quantitative precipitin reaction 
was performed on the various preparations. Two labeled antibody solu- 
tions were prepared by varying the molar ratio of the diazonium salt 
to the antibody. The first was prepared at  a molar ratio of 20/1; the 
second with a ratio of 100/1. The quantitative precipitation curves  a r e  
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shown in Figure 2. These results indicated that aboue 0.4% B (natural 
Fig. 2 
~~ 
isotopic abundance) had been incorporated into the protein system with 
a concomitant loss of about 25% of the precipitating ability of the anti- 
body. 
These preliminary results with the BSA -anti-BSA system proved that 
suitable boron -containing compounds can be incorporaxed into antibody 
proteins under sufficiently mild conditions such a s  to maintain the spe- 
cificity of the antibody. 
Human Lymphocyte System. Since nearly a l l  neoplastic cells thus far 
studied in detail appear to possess tumor associated antigens which 
induce I an immune response in competent hosts, cancer research 
(11) G. Klein, Federation Proceedings, rcN 28, 1739 (1969). 
should benefit by the development and exploitation of this technique. 
Neutron-capture therapy using OB -conjugated antibodies allows a new 
approach to cancer therapy; one that combines the great tumor specificity 
of antibodies with the known 10 B thermal neutron capture reaction. This 
method would thus limit and localize the destruction of tissue to tumor 
cells which carry 'OB-labeled tumor specific antibodies a t  the time of 
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neutron irradiation. 
Human histocompatibility antigens a r e  also cell 
voke antibodies when introduced into an allogeneic host. Since more is 
known about the antigens and antibodies formed in multiparous females, 
the transplantation system was adopted a s  a model x- the development 
of the test. The test for lymphocyte killing was adapted from Terasaki's 
lymphocytotoxicity test and possesses the advantage of microassays. 
It is presently used in most histocompatibility testin 
r antigens and in- 
12 
(12) P. I. Terasaki and J. D. McClelland, Nature, 206, 998 (1964) 
Nw 
To ascertain the feasibility of in vitro lymphocyee killing by zhe 
aIpha particle ernlirted from nefitron i r r e d k t e d  'OB, p r i f i e d  peripheral 
-- 
blood lymphocytes were  tested in boron -containing solutions of varying 
concentrations. In this test the boron was added as B H a c o m -  
13 pound which exhibits a low toxicity 
2 10 10' 
(LD50 = 1025 mg/kg) and non- 
(13) E. L. Muetterties, J. H. Balthis, Y. T. Chia, W. H. Knoth, 
and H. C. Miller, Inorg. Chem., 3, 444 (1964). 
N 
R 
specific absorption to cellular material. Similar studies using sodium 
pentaborate in vivo have been reported. The thermal neutron source 4 -- 
12 was the UCLA R-1 l O O K W  nuclear reactor with a core flux of 1.5 x l o  
2 neutrons/cm -sec. 
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The results of the neutron radiation experiment using lymphocytes 
and K2B10H10 a r e  shown in Figure 3. 
Fig. 3 
For the initial studies with boron -conjugated antibodies, a strong 
multispecific antiserum was selected. Among the specificities possessed 
by this antiserum were HL-A 1,2 ,3 ,9 ,  and Te5S. Since nearly 50% of 
the population car ry  the HLA -2 antigen, lymphocytes needed for the 
tests were  relatively easy to obtain. 
The 7 s  fraction. of the serum was isolated by passage of the serum 
through Sephadex G-200. The coupling reaction between the antibody 
containing fraction and the boron -containing diazonium compound was 
allowed to proceed a t  4' in an aqueous phosphate buffered saline (pH= 
7.4)  media. The antibody was purified and analyzed for total boron 
(0.2%). 
The antibody preparation was tested against cells which carried the 
HL-A specificity. The results of the neutron radiation experiments 
which varied both the a'ntibody Concentration and radiation time a re  
shown in Figure 4. The initial antibody concentration was 15 mg/ml. 
Fig. 4 
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These results indicate that the binding of the boron-conjugated spe- 
cific antibody brought the boron atoms close enough to the cells so that 
the @-particle disintegration product formed from neutron capture by 
'OB destroyed the lymphocytes. That the conjugation of the boron- 
containing label to antibody molecules did not affect the antibody spe- 
cificity was shown by the cytotoxic effect in the test with complement 
employing this antibody preparation. The complement cytotoxic test 
using normal and boron -labeled antibodies gave similar results' for the 
antibody activity . 
The results obtained by varying the total boron concentration and 
the radiation time shown in Figures 3 and 4, were compared in order 
to demonstrate the ability of the antibody to concentrate the boron- 
eontai-ning label on the cell. From Figure 3, 2 pg B/@l gave 30% s u r -  
vival after 2 minutes of neutron radiation. From Figure 4, an antibody 
titer of 1:8 gave 30% survival after 2 minutes of radiation. The antibody 
4 
contained 0.2% B. The concentration of the antibody and boron a t  this 
dilution (1:8) was 1:87 pg Ab/$ and 3.8 x pg B/pL Comparison of 
the total boron concentration required to give a comparable level of 
cellular destruction in the two experiments indicates that if the boron 
is first incorporated into a specific antibody the boron is approximately 
500 times more effective in causing cellular destruction than a non- 
specifically bound boron compound. 
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Mouse His  tocompatibility Sys tem. Antibodies directed against the 
CS7 B l l O  mouse strain were prepared in the C3H mouse strain. The 
C3H a n t i 4 3 7  B l l O  antibody (7s fraction) was conjugated with the boron- 
containing labeling reagent in the usual  manner. The boron-labeled 
antibody solution containing 2% of available boron as 'OB was then in- 
cubated with C3H lymphocytes and C57 B l l O  lymphocytes. The cells 
were washed with tissue culture media and subjected to neutron radia- 
tion. The results obtained a r e  shown in Figure 5. The C3H lympho- 
cytes survived the radiation since the boron-containing antibody was 
completely removed by washing with tissue cul ture  media. The C57 
B l l O  lymphocytes exhibited a marked decrease in survival owing to 
the specific binding of boron-containing antibody to the histocompati- 
bility antigens against which the antibody was directed. This procedure 
of removal of excess antibody prior to radiation experiments indicates 
that specific antibodies, when labeled with 'OB, will  destroy only those 
cells which exhibit the antigen necessary for binding the boron -labeled 
antibody. Thus,  in principle, the excess boron-containing antibodies 
can be removed prior to radiation of cancer patients in order to limit 
cellular destruction in non -neoplastic regions. 
Cellular Incorporation of Elemental Boron. An additional mechanism 
which is  operative in the immune response is the promotion of phagocytic 
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14 activity. Phagocytosis is performed by polymorphonuclear leukocytes 
(14) W. S. Hammond in "Biology of the Immune Response, " P. 
Abramoff and M. LaVia, Ed., McGraw-Hill, 1970, Chapter 13. 
and macrophage cells; the latter include monocytes in the bloodstream, 
the lining of cells of the sinusoids of the liver, bone marrow, lymph 
nodes, and spleen. It was anticipated that owing to increased phagocytic 
activity it would be possible to incorporate elemental boron within the 
cell owing to its particulate nature. 
Elemental boron (natural isotopic abundance) (1 -1 0~ particle size) 
was added to Walker 256 cloned cells in tissue culture media. After 
2.5 Wmrs 78% of the cells exhibited visible boron incorporation within 
the-cell. The cells containing the boron were removed with trypsin and 
replated, washing away the excess boron particles which had not been 
/- 
absorbed. One-half the cells were subjected to a 30 minute neutron 
irradiation, the other half were used a s  a control. Immediately foflow- 
ing the neutron radiation both sets of cells appeared normal and no dif - 
ferences were noted under an inverted microscope with 40X objective. 
However, after 21 hours the cells subjected to neutron radiation had 
fragmented and were dead, whereas the boron -containing cells which 
had not been irradiated were normal. In a separate control experiment 
it was determined the W256 cells suffered no ill effects when subjected 
to 1 hour of neutron radiation. 
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The difference in the time limit for neutron 
era1 blood lymphocytes and W256 cells reflects 
in the radio-sensitivity of cells. In addition, 
radiation between periph- 
only a major difference 
the alpha particle 
(15) A.  P. Casarett, "Radiation Biology, " Prentice-Hall, Englewood 
Cliffs, N. J . ,  1968. 
11 produced from B fission causes observable damage to lymphocytes 
immediately, while the alpha particle damage in W256 cells is more 
delayed. 
Conchs ions 
These xesul ts  ohainecl using boron -iabeled antibodies and eierrienral 
boron in natural abundance strongly suggest that the concept of incor- 
porating boron into proteins or polymers which exhibit marked tumor 
- 
specificity is of great potential for u s e  in neutron-capture cancer therapy. 
One additional and important aspect of the use of boron-labeled antibodies 
is that the antibodies when bound to the cell define the region of cellular 
destruction so that the exact dimensions of the neoplasms do not need 
to be determined a s  in other forms of radiation treatment. 
The boron-containing labeling compound used in this study and the 
method of conjugation to the protein had little effect on the specificity 
of the antibody and exhibited no cellular toxicity a t  the concentrations 
used in these studies. In addition, use of highly 'OB enriched labeling 
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compound could increase the effectiveness of cellular destruction by a s  
much a s  fivefold. 
Experimental 
1 -(4 -aminophenyl) -1 , 2-carborane was prepared by the literature 
procedure. lo Nitrogen and boron analyses were performed using standard 
analytical procedures. 6 2  l7 Protein concentrations were determined 
(16) G. Ingram, "Organic Elemental Microanalysis, " Reinhold, 
New York, 1962, Chapter 3. 
(17) A .  Kaczmarczyk, J. R. Messer, and C. E. Pierce, Anal. Chem. 
43, 271 (1971). 
Ny 
18 spectrophotometrically. The neutron radiation experiments were  per - 
- -7 
/ 
(18) T. H. The and T. E. W. Feltkamp, Immunology, 18, 865 (1970. 
rcM 
formed in the thermal column of the UCLA R-1 reactor. The thermal 
neutron flux with the reactor operating a t  100 I<w is 1.5 x 10 
trons/cm -sec, which was determined by standard gold foil radiation 
10 neu-  
- 2  
techniques. 
Diazotization of 1 -(4-aminophenyl)-l , 2-carborane. A general procedure 
was used for diazotization and suitable aliquots of aqueous solutions of 
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the diazonium salt were used in subsequent labeling experiments. 
1 -(4-aminophenyl)-l-2 carborane (24 mg, 0.1 mM) was  added to 
0.3 ml of 1 M aqueous HC1 in an ice bath. A sodium nitrite solution 
(7 ml, 1 mg/ml) was added and the mixture allowed to stir for 1/2 
hour. The solution was filtered and diluted to L5.0 ml witll 0.01 M 
aqueous HCI. Owing to the reactive nature of the diazonium salt, the 
solutions must be kept cold and slightly acidic to retard decomposition. 
The diazonium solution was stable for at least 3 hours if kept in an ice 
.bath. 
The concentration of the diazonium salt was  determined spectro- 
photometrically. A suitable aliquot (-10 $) of the above solution was 
added to a 0.01 M (10 ml) solution of fj -naphthol in 95% ethanol. A f t e r  
4 30 minutes the ahsnrhance was determined st 485 m F  (e485 = 1 .98x  10 ). 
BSA -anti-BSA Reaction. Bovine serum albumin (BSA) and the 7s fraction 
of rabbit anti -bovine serum albumin (lyophilized) w e r e  obtained corn - 
mercially and used a s  received. l9 A l l  solutions w e r e  prepared in an 
(19) Nutritional Biochemicals Corporation, 26201 Miles Road, 
Cleveland, Ohio, 44128. 
aqueous phosphate buffer (pH = 8.0). The precipitin reaction was per- 
formed by the literature method. The initial concentrations of BSA and 
anti-BSA were 10 mg/ml and 15 mg/ml, respectively. 
8 
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Two separate boron -labeled anti -BSA solutions were prepared by 
varying the molar ratio of the diazonium salt to anti-BSA during the 
coupling reaction. The labeled anti -BSA solution obtained from the 
cobpling reaction with a molar ratio (diazonium/anti-BSA) of 20/1 (11) 
and 100/1 (111) w e r e  used in the precipitin reaction. A third precipitin 
reaction was performed using BSA and unmodified ami-BSA (I). 
Suitable aliquots of the diazonium solution were  added to the anti- 
BSA solution at  4' at pH 8.0. The pH was maintained at  8.0 by drop- 
wise addition of 0. l . M  NaOH. The resulting yellow solution (A 
350 mp) was allowed to s t i r  for 24 hours at 4'. The mixture was cen- 
= 
max 
trifuged to remove the decomposed diazonium salt which had not cou- 
pled to the anti-BSA. The clear yellow supernatant was dialyzed for 
48 hours against phosphate-buffered saline. The solution was per- 
vapora .ted to the original volume and the prec .ipi t in reaction performed. 
Human and Mouse Histocompatibility Boron-labeled Antibodies. The 7 s  
fraction of serum was obtained by gel filtration through Sephadex G-200 
with phosphate -buffered saline. The 7s fraction w a s  concentrated by 
negative pressure dialysis. 
'The labeling experiments were performed as outrHined previously 
using a molar ratio of 10 diazonium/l antibody. The coupling reaction 
was allowed to proceed for 3 hours at  4' in a phosphate-buffered saline 
solution (pH = 7 .4 ) .  The yellow solution was passed tthrough Sephadex 
G-25 with phosphate-buffered saline to remove the 
salt. The effluent was again concentrated by negative pressure dialysis. 
reacted diazonium 
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Boron-labeled antibody solutions (I pl) of different concentrations 
20 
were  added to the wells of a microtest plate under  5 p1 of mineral oil. 
(20) Falcon Plastics, Los Angeies, California. 
The oil is added to the well  first to prevent the minute amounts of re- 
agents from drying. A thousand purified, peripheral blood lymphocytes 
suspended in 1 p l  of McCoy's medium were  added to each well. Follow- 
ing neutron radiation, eosin red was added to each well and the test ter- 
minated by fixation of the cells with formalin. The tray was prepared 
for reading in an inverted phase microscope. Live cells in this test 
appear bright, clear and unstained while dead cells a r e  dark and diffuse. 
Lymphocytotoxic assays were  performed on all boron-labeled anti - 
body solutions. A f t e r  one-half hour incubation of the cells W i t h  the anti- 
body, 5 p1 of rabbit complement was added to each well followed by an 
additional one hour of incubation. Eosin red was then added to each well  
to stain dead cells and the test was fixed with formalin. Each of the 
boron-labeled antibody preparations gave an antibody activity titer iden - 
tical to the unmodified antibody. 
For neutron radiation experiments with the excess boron -labeled 
antibody removed (mouse histocompatibility system), boron -labeled 
antibody solutions a t  fu l l  strength w e r e  allowed to react with cells for 
one hour. The cells were then centrifuged and washed twice in tissue 
culture media. Antibody -coated lymphocytes w e r e  then adjusted to give 
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1000 cells in 1 $ and dispensed into the wells of a microtest plate under 
oil. The plates were  treated in the same manner as described previously. 
Intercellular Incorporation of Particulate Boron. Six control and six ex - 
6 perimental small flasks were each plated with 0.28 x 10 Walker 256 
cloned cells. The cells in the experimental flasks were allowed to take 
up boron particles from a saline solution added to their medium. The 
cells were left in contact with the particulate boron for 2.5 hours and 
then removed with trypsin and replated on small flasks. Seventy eight 
percent of the cells had visible uptake boron. About: 40 minutes after the 
small flasks were incubated at  37' in growth medium containing 20% fetal 
calf serum, the cells were subjected to neutron radiation for 30 minutes. 
The controls which had no boron incorporation showed no change after 
the radiation. Three flasks containing cells with boron were not i r r a -  
diated to determine any toxic effects of the boron, the three other flasks 
with boron were irradiated for 30 minutes. A l l  flasks were  examined 
following the radiation experiment and no differences were  noted under 
inverted sc.ope with 40X objective. An additional 2 mi  of regular growth 
medium was added to each flask before replacing them in the incubator. 
Af t e r  21 hours both sets of control cells (no boron and irradiated, and 
boron with no irradiation) all appeared normal, while the cells with 
boron and irradiation were all now fragmented, floating and dead. 
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Figure 2. Precipitin reaction between bovine serum albumin (BSA) 
and rabbit anti-bovine serum albumin (anti-BSA). 
I BSA + 7s anti-BSA 
I1 BSA + 7s anti-BSA (labeled) complex containing 0.35% B 
I11 BSA + 75 anti-BSA (labeled) complex containing 0.38% B 
w 
Figure 3. Survival curves for peripheral blood lymphocytes with 
KZBIOHIO solutions. 
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Figure 4. Effect of titration of boron-labeled antibody on survival of 
peripheral biood lymphocytes. Initial antibody concentra- 
tion = 15 mg/ml; 0.20% B. 
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Figure 5. Survival of C3H and C57BllO peripheral blood lymphocytes 
.-- 
after incubation with boron -labeled C3H anti -C57B110 antibody. . I  
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